XML 49 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Description of Business - Schedule Of Restated Condensed Consolidated Statement of Operations (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]            
Research and development $ 12,747   $ 7,496   $ 26,673 $ 14,431
Total operating expenses 27,019   10,851   53,981 20,620
Loss from operations 25,758   9,676   51,030 17,357
Change in fair value of derivative warrant liabilities (7,980)   0   (11,750) [1] 0
Change in fair value of earn-out liability (6,566)   0   (12,557) [1] 0
Total other (expense) income, net 13,506   (398)   21,136 (504)
Net loss $ (12,252) [1] $ (17,642) [1] $ (10,074) $ (7,787) $ (29,894) [1] $ (17,861)
Net loss per share attributed to common stockholders—basic $ (0.11)   $ (0.46)   $ (0.36) $ (0.82)
Net loss per share attributed to common stockholders—diluted $ (0.11)   $ (0.46)   $ (0.36) $ (0.82)
As Reported            
Error Corrections and Prior Period Adjustments Restatement [Line Items]            
Research and development $ 12,634       $ 25,083  
Total operating expenses 26,906       52,391  
Loss from operations (25,645)       (49,440)  
Change in fair value of derivative warrant liabilities 8,687       14,509  
Change in fair value of earn-out liability 8,024       17,658  
Total other (expense) income, net 15,671       28,996  
Net loss $ (9,974)       $ (20,444)  
Net loss per share attributed to common stockholders—basic $ (0.09)       $ (0.24)  
Net loss per share attributed to common stockholders—diluted $ (0.09)       $ (0.24)  
To Be Adjusted (a)            
Error Corrections and Prior Period Adjustments Restatement [Line Items]            
Research and development $ 0       $ 0  
Total operating expenses 0       0  
Loss from operations 0       0  
Change in fair value of derivative warrant liabilities 0       0  
Change in fair value of earn-out liability (1,458)       (5,101)  
Total other (expense) income, net (1,458)       (5,101)  
Net loss (1,458)       (5,101)  
To Be Adjusted (b)            
Error Corrections and Prior Period Adjustments Restatement [Line Items]            
Research and development 113       1,590  
Total operating expenses 113       1,590  
Loss from operations (113)       (1,590)  
Change in fair value of derivative warrant liabilities 0       0  
Change in fair value of earn-out liability 0       0  
Total other (expense) income, net 0       0  
Net loss (113)       (1,590)  
To Be Adjusted (c)            
Error Corrections and Prior Period Adjustments Restatement [Line Items]            
Research and development 0       0  
Total operating expenses 0       0  
Loss from operations 0       0  
Change in fair value of derivative warrant liabilities (1,331)       0  
Change in fair value of earn-out liability 0       0  
Total other (expense) income, net (1,331)       0  
Net loss (1,331)       0  
To Be Adjusted (d)            
Error Corrections and Prior Period Adjustments Restatement [Line Items]            
Research and development 0       0  
Total operating expenses 0       0  
Loss from operations 0       0  
Change in fair value of derivative warrant liabilities 624       (2,759)  
Change in fair value of earn-out liability 0       0  
Total other (expense) income, net 624       (2,759)  
Net loss 624       (2,759)  
To Be Adjusted            
Error Corrections and Prior Period Adjustments Restatement [Line Items]            
Research and development 113       1,590  
Total operating expenses 113 1,500     1,590  
Loss from operations (113) $ (1,300)     (1,590)  
Change in fair value of derivative warrant liabilities (707)       (2,759)  
Change in fair value of earn-out liability (1,458)       (5,101)  
Total other (expense) income, net (2,165)       (7,860)  
Net loss $ (2,278)       $ (9,450)  
Net loss per share attributed to common stockholders—basic $ (0.02)       $ (0.12)  
Net loss per share attributed to common stockholders—diluted $ (0.02)       $ (0.12)  
As Restated            
Error Corrections and Prior Period Adjustments Restatement [Line Items]            
Research and development $ 12,747       $ 26,673  
Total operating expenses 27,019       53,981  
Loss from operations (25,758)       (51,030)  
Change in fair value of derivative warrant liabilities 7,980       11,750  
Change in fair value of earn-out liability 6,566       12,557  
Total other (expense) income, net 13,506       21,136  
Net loss $ (12,252)       $ (29,894)  
Net loss per share attributed to common stockholders—basic $ (0.11)       $ (0.36)  
Net loss per share attributed to common stockholders—diluted $ (0.11)       $ (0.36)  
[1] For discussion on the restatement adjustments, see Note 1 — Description of Business — Restatement of Condensed Consolidated Financial Statements and Immaterial Correction of Prior-Period Errors